• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by BrainsWay Ltd. (Amendment)

    2/14/23 8:02:19 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care
    Get the next $BWAY alert in real time by email
    SC 13G/A 1 d9944575_13g-a.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    BrainsWay Ltd.
    (Name of Issuer)

     

     

    Ordinary Shares, par value NIS 0.04 per share
    (Title of Class of Securities)

     

     

    10501L106
    (CUSIP Number)

     

     

    December 31, 2022
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [x] Rule 13d-1(b)

     

    [_] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     
     

     


    CUSIP No
    10501L106    
         
    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Masters Capital Management, LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Georgia  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      1,800,000  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      1,800,000  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      1,800,000  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.4%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    OO, IA

     
             

     

     
     

     

     


    CUSIP No
    10501L106    
         
    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Michael Masters  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      1,800,000  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      1,800,000  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      1,800,000  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.4%  
         
    12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    IN, HC

     
             
     
     

     

      Item 1. (a). Name of Issuer:  
             
          BrainsWay Ltd.  
           
      (b). Address of issuer's principal executive offices:  
           
       

    19 Hartum Street

    Bynet Building, 3rd Floor

    Jerusalem, 9777518, Israel

     
           
    Item 2. (a). Name of person filing:  
           
       

    Masters Capital Management, LLC

    Michael Masters

     
           
      (b). Address or principal business office or, if none, residence:  
           
       

    Masters Capital Management, LLC

    3060 Peachtree Road, Suite 1425

    Atlanta, Georgia 30305

    United States of America

     

    Michael Masters

    c/o Masters Capital Management, LLC

    3060 Peachtree Road, Suite 1425

    Atlanta, Georgia 30305

    United States of America

     
           
      (c). Citizenship:  
           
       

    Masters Capital Management, LLC – Georgia Limited Liability Company

    Michael Masters – United States of America

     
           
      (d).   Title of class of securities:  
           
        Ordinary Shares, par value NIS 0.04 per share  
           
      (e). CUSIP No.:  
           
        10501L106  
               

     

    Item 3.   If This Statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a

     

      (a) [_] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

      (b) [_] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

     
     

     

     

      (c) [_] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

      (d) [_] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

      (e) [X] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

      (g) [X] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);

     

      (i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

      (j)   [_] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

      (k)   [_] Group, in accordance with § 240.13d-1(b)(1)(ii)(K).  If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
               

     

     

    Item 4. Ownership.

     

      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)   Amount beneficially owned:
         
       

    Masters Capital Management, LLC – 1,800,000

    Michael Masters – 1,800,000

     

      (b)   Percent of class:
         
       

    Masters Capital Management, LLC – 5.4%

    Michael Masters – 5.4%

     

      (c)   Number of shares as to which the person has:

     

        (i) Sole power to vote or to direct the vote    
         

    Masters Capital Management, LLC – 0

    Michael Masters – 0

     
             
     
     

     

        (ii)   Shared power to vote or to direct the vote  
         

    Masters Capital Management, LLC – 1,800,000

    Michael Masters – 1,800,000

     
             
        (iii) Sole power to dispose or to direct the disposition of  
         

    Masters Capital Management, LLC – 0

    Michael Masters – 0

     
             
        (iv)   Shared power to dispose or to direct the disposition of  
         

    Masters Capital Management, LLC – 1,800,000

    Michael Masters – 1,800,000

       
             

     

    Item 5. Ownership of Five Percent or Less of a Class.
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [  ].
     

     

    N/A

       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
      If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified.  A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
       
       
      N/A
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
     

    If a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

     

      See Exhibit B attached hereto.
       

     

     
     

     

     

    Item 8. Identification and Classification of Members of the Group.
       
     

    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.

     

      N/A
       
       
    Item 9. Notice of Dissolution of Group.
       
     

    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

     

      N/A
       
       
    Item 10. Certification.
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
       

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

     

     

    MASTERS CAPITAL MANAGEMENT, LLC*

     

    By: /s/ Michael Masters

    Michael Masters
    Managing Member

     

     

    MICHAEL MASTERS*

     

    /s/ Michael Masters

     

    Date: February 14, 2023

     

    *Each Reporting Person disclaims beneficial ownership over the securities reported herein except to the extent of its pecuniary interest therein.

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

     

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     
     

    EXHIBIT A

     

    AGREEMENT

     

    The undersigned agree that this Amendment 1 to Schedule 13G dated February 14, 2023 relating to the Ordinary Shares, par value NIS 0.04 per share of BrainsWay Ltd. shall be filed on behalf of the undersigned.

     

     

     

    MASTERS CAPITAL MANAGEMENT, LLC

     

    By: /s/ Michael Masters

    Michael Masters
    Managing Member

     

     

    MICHAEL MASTERS

     

    /s/ Michael Masters

     

     

    Date: February 14, 2023

     

     

     

     

     
     

     

    EXHIBIT B

     

     

    Michael Masters has beneficial ownership by virtue of his role as a control person of Masters Capital Management, LLC.

     

     

     

     

     

    Get the next $BWAY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BWAY

    DatePrice TargetRatingAnalyst
    11/16/2023Outperform → Mkt Perform
    Raymond James
    3/3/2022$15.00Buy
    Loop Capital
    11/29/2021$14.00 → $15.00Buy
    HC Wainwright & Co.
    8/12/2021$17.00 → $14.00Buy
    HC Wainwright & Co.
    7/19/2021$17.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BWAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Brainsway downgraded by Raymond James

      Raymond James downgraded Brainsway from Outperform to Mkt Perform

      11/16/23 7:31:55 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • Loop Capital initiated coverage on BrainsWay with a new price target

      Loop Capital initiated coverage of BrainsWay with a rating of Buy and set a new price target of $15.00

      3/3/22 4:42:28 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • HC Wainwright & Co. reiterated coverage on BrainsWay with a new price target

      HC Wainwright & Co. reiterated coverage of BrainsWay with a rating of Buy and set a new price target of $15.00 from $14.00 previously

      11/29/21 6:24:14 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care

    $BWAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by BrainsWay Ltd.

      SC 13G/A - Brainsway Ltd. (0001505065) (Subject)

      11/14/24 1:33:58 PM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by BrainsWay Ltd.

      SC 13G/A - Brainsway Ltd. (0001505065) (Subject)

      11/14/24 1:32:48 PM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D filed by BrainsWay Ltd.

      SC 13D - Brainsway Ltd. (0001505065) (Subject)

      11/13/24 6:09:51 PM ET
      $BWAY
      Medical/Dental Instruments
      Health Care

    $BWAY
    Financials

    Live finance-specific insights

    See more

    $BWAY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BrainsWay Reports First Quarter 2025 Financial Results and Operational Highlights

      Achieved record quarterly sales of $11.5 million in Q1 2025, an increase of 27% compared to Q1 2024 Operating profit totaled $0.6 million and Adjusted EBITDA rose to $1.3 million, increasing by 519% and 81%, respectively, compared to Q1 of 2024 Shipped a record net number of Deep TMS Systems, indicating significant demand and further strengthening of relationships with enterprise accounts Company is reiterating its full-year 2025 financial guidance, including revenue of $49 to $51 million, operating profit of 3% to 4% and Adjusted EBITDA of 11% to 12% Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, May 13, 2025 (GLOBE NEWSWIRE) --

      5/13/25 7:30:00 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • BrainsWay to Report First Quarter 2025 Financial Results on May 13, 2025

      BURLINGTON, Mass. and JERUSALEM, April 29, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its first quarter 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Tuesday, May 13, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time the same day to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Tuesday, May 13, 2025Time:8:30 AM Eastern TimeUnited States:1-877-300

      4/29/25 8:00:00 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • BrainsWay Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

      Achieved record quarterly sales of $11.4 million in Q4 2024, an increase of 27% compared with Q4 2023 Full year 2024 revenue increased nearly 30% YoY to $41 million Exceeded full year 2024 operating income and Adjusted EBITDA margin guidance Company expects continued strong growth in 2025, with revenue of $49 million to $51 million and further improvement in profit and profitability Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, March 11, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported fourth qua

      3/11/25 7:30:00 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • BrainsWay Reports First Quarter 2025 Financial Results and Operational Highlights

      Achieved record quarterly sales of $11.5 million in Q1 2025, an increase of 27% compared to Q1 2024 Operating profit totaled $0.6 million and Adjusted EBITDA rose to $1.3 million, increasing by 519% and 81%, respectively, compared to Q1 of 2024 Shipped a record net number of Deep TMS Systems, indicating significant demand and further strengthening of relationships with enterprise accounts Company is reiterating its full-year 2025 financial guidance, including revenue of $49 to $51 million, operating profit of 3% to 4% and Adjusted EBITDA of 11% to 12% Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, May 13, 2025 (GLOBE NEWSWIRE) --

      5/13/25 7:30:00 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • BrainsWay to Showcase Deep TMS at the 2025 American Psychiatric Association Annual Meeting in Los Angeles

      BURLINGTON, Mass. and JERUSALEM, May 01, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, is proud to announce its participation at the American Psychiatric Association (APA) Annual Meeting, taking place May 17–21, 2025, in Los Angeles, California. As part of the meeting's educational programming, there will be a full day master course on Sunday, May 18, 2025, entitled: "Clinical Applications for Psychiatric Practice: Ketamine and TMS." The course will provide an in-depth look at the integration of novel treatments into clinical psychiatric practice, highlighting practical approa

      5/1/25 8:00:00 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • BrainsWay to Report First Quarter 2025 Financial Results on May 13, 2025

      BURLINGTON, Mass. and JERUSALEM, April 29, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its first quarter 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Tuesday, May 13, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time the same day to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Tuesday, May 13, 2025Time:8:30 AM Eastern TimeUnited States:1-877-300

      4/29/25 8:00:00 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care

    $BWAY
    SEC Filings

    See more
    • SEC Form 6-K filed by BrainsWay Ltd.

      6-K - Brainsway Ltd. (0001505065) (Filer)

      5/13/25 7:30:06 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • SEC Form 424B3 filed by BrainsWay Ltd.

      424B3 - Brainsway Ltd. (0001505065) (Filer)

      5/1/25 7:00:47 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by BrainsWay Ltd.

      EFFECT - Brainsway Ltd. (0001505065) (Filer)

      5/1/25 12:15:26 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care

    $BWAY
    Leadership Updates

    Live Leadership Updates

    See more
    • BrainsWay Appoints Richard A. Bermudes, M.D. as Chief Medical Officer

      BURLINGTON, Mass. and JERUSALEM, Aug. 29, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Richard A. Bermudes, M.D. as Chief Medical Officer (CMO), effective September 1, 2024. Dr. Aron Tendler, M.D., who has served as CMO since 2015, will continue to serve as a collaborator on important strategic research projects. "We are excited to have Richard join our team to lead and shape BrainsWay's clinical strategy and product roadmap. His extensive experience with TMS and brain stimulation therapies as a practicing phys

      8/29/24 7:30:00 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care
    • Murchinson Takes Action to Replace Board of Directors of Nano Dimension at Upcoming Annual General Meeting

      Highlights Entrenchment Tactics Taken by the Board Before and Following March Special Meeting Where Shareholders Overwhelmingly Supported Murchinson's Case for Change – Including the Removal of CEO and Chairman Yoav Stern From the Board Puts Forward Proposals to Improve Company's Failed Corporate Governance by Seeking to Remove All Current Directors and Appoint Five New, Experienced and Independent Nominees Murchinson Ltd. (collectively with its affiliates and funds it advises and/or sub-advises, "Murchinson" or "we"), a significant shareholder with approximately 5.9% of the outstanding shares of Nano Dimension Ltd., a company incorporated in Israel (NASDAQ:NNDM) ("Nano Dimension" or th

      8/3/23 3:00:00 PM ET
      $BWAY
      $INSG
      $MCK
      $NNDM
      Medical/Dental Instruments
      Health Care
      Telecommunications Equipment
      Telecommunications
    • BrainsWay Announces Appointment of Ido Marom as CFO

      BURLINGTON, Mass. and JERUSALEM, May 23, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Ido Marom, an experienced senior financial leader in global industries, including medical technology, as Chief Financial Officer (CFO). Mr. Marom will succeed Scott Areglado, who will be stepping down from the Company to pursue other opportunities. "We are thrilled to welcome Ido and his extensive financial expertise to BrainsWay," stated Hadar Levy, BrainsWay's Chief Executive Officer. "He has led the financial strategy and i

      5/23/23 7:30:00 AM ET
      $BWAY
      Medical/Dental Instruments
      Health Care